Drugs / VNX-202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07192432 | Nov 2025 → Sep 2033 expected | — | Vironexis Biotherapeutics Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VNX-202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07192432 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “VNX-202 is an investigational adeno-associated virus (AAV) gene therapy” NCT07192432 ↗ |
| Route | Intravenous | “Single IV Infusion” NCT07192432 ↗ |